George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Strong recovery from Revolution Bars, Vitec

Tue, 01st Mar 2022 18:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

PPHE Hotel Group Ltd - Amsterdam-based hotel owner and operator - For 2021, pretax loss narrows to GBP57.6 million from GBP94.7 million the year before, on revenue which grows 39% year-on-year to GBP141.4 million from GBP101.8 million, which marks a recovery to 40% of company's 20219 levels. RevPAR rises 22% to GBP35.9 from GBP29.4, and occupancy improves to 30.7% from 28.0% the prior year. Stronger performance is buoyed by the vaccination rollout in several countries, and the easing of Covid-related restrictions from the second quarter onwards. Will not declare a dividend for 2021, but will review future payouts depending on the recovery trajectory.

----------

Vitec Group PLC - Richmond, west London-based photography and video products maker - For 2021, swings to pretax profit of GBP29.6 million from a loss of GBP7.7 million, on revenue which grows 36% year-on-year to record levels of GBP394.3 million from GBP290.5 million, with increases across all divisions reflecting a strong market recovery. Declares final dividend of 24.0 pence per share, bringing the total payout to 35.0p, hiked from 4.5p. Looking ahead, Vitec says 2022 started well with record order intake, and remains confident despite short-term component shortages and inflation. Also looking to change group name at 2022 annual general meeting.

----------

Revolution Bars Group PLC - Ashton-under-Lyne, England-based bar chain - For the 26 weeks ended January 1, swings to pretax profit of GBP4.3 million from loss of GBP17.7 million the same period a year before, as total sales more than triple to GBP74.1 million from GBP21.6 million, aided by relaxed restrictions, allowing the return of students, office workers and increased staycations. Looking ahead, return to like-for-like sales growth in February, and expects annual adjusted earnings before interest, tax, depreciation and amortisation to be at the top end of market expectations, which is set between GBP8.0 million and GBP10.0 million.

----------

Volvere PLC - turnaround investment firm based in Leamington Spa, England - For 2021, expects to report a pretax profit of around GBP70,000, swinging from a loss of GBP550,000 the year before, on revenue which is set to grow 16% year-on-year to GBP35.6 million from GBP30.8 million, driven by a stronger performance from Shire Foods and Indulgence Patisserie Ltd. Looking ahead, challenges related to cost increases and labour availability in 2021 are present in 2022, however, environment for turnaround investing is improving.

----------

Uniphar PLC - Dublin-based healthcare services firm - For 2021, pretax profit increases 32% to EUR50.4 million from EUR38.4 million, on revenue which grows 6.5% year-on-year to EUR1.94 billion from EUR1.82 billion, with growth from all businesses, particularly Supply Chain & Retail which exceeds gross profit guidance. Looking ahead, keeps medium term guidance of mid-single digit growth in Commercial & Clinical, double-digit from Product Access and low-single digit in Supply Chain & Retail.

----------

essensys PLC - London-based software and cloud services for flexible workspace industry - For the six months ended January 31, revenue increases 3% year-on-year to GBP10.9 million, with continued demand from existing and new customers. Leads to anticipation that adjusted loss before interest, tax, depreciation and amortisation will be slightly better than management expectations. Looking ahead, to full year, adjusted Lbitda is set to be no more than GBP7 million, and revenue is expected to be at least GBP23.5 million, up 6.8% from GBP22 million the prior year. However, expansion and acceleration of its go-to-market activities has been delayed by "continued Covid related uncertainty". Also results in extended sales cycles leading to lower-than-anticipated sales bookings year-to-date.

----------

Fiske PLC - London-based stockbroker and investment manager - For the six months ended November 30, pretax loss narrows to GBP6,000 from GBP103,000 the same period a year before, as revenue grows 6% year-on-year to GBP2.9 million from GBP2.7 million, driven by a rise in investment management fee income on new client wins, more than offsetting a drop in commission income as market conditions were less volatile.

----------

PCI-PAL PLC - London-based call centre software provider - For the six months ended December 31, pretax loss narrows to GBP1.1 million from GBP2.3 million, on revenue which grows 72% year-on-year to GBP5.5 million from GBP3.2 million, as total annual contract value rises 36% to GBP11.3 million from GBP8.3 million. Looking ahead, makes strong start to the second half, with revenue momentum and the launch of its Australian business.

----------

Calnex Solutions PLC - provider of test and measurement solutions for the telecommunications sector - Reports strong levels of trading in the six months ending September 31, and subject to the fulfilment of scheduled orders in March, results for the year ending March 31 are set to e in line with market expectations. Calnex is on-track to begin the 2023 financial year with a record order book across all product lines, leading to revenue and operating profit for the year being set to come ahead of market expectations.

----------

European Smaller Companies Trust PLC - fund that seeks capital growth by investing in smaller companies in Europe outside the UK - For the six months ended December 31, net asset value total return is negative 1.4%, compared to the Euromoney Smaller European Cos (ex-UK) index, which made a positive return of 4.1%. As at December 31, net asset value per share drops 2.4% to 204.69 pence from 209.71p at the end of June. Declares dividend per share of 1.25 pence, up 22% from 1.025p a year prior.

----------

GetBusy PLC - Cambridge, England-based document management and productivity software provider - For 2021, pretax loss widens to GBP2.3 million from GBP1.1 million on rising costs, which more than offset a 8.5% rise in revenue to GBP15.4 million from GBP14.2 million, as annual recurring revenue grows 16% to GBP15.8 million, due to new business and ongoing demand. Looking ahead, for 2022 adjusted Ebitda is expected to approach breakeven, while strong ARR momentum will have group revenue at no less than GBP17.0 million.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis - For the six months ended December 31, pretax loss widens to AUD7.6 million from AUD5.9 million, due to higher administrative costs and one-off impairments arising from the MedicaNL acquisition. This was in spite of revenue more than tripling to AUD2.6 million from AUD741,911 through strong sales of Artemic, its Covid-19 supplement.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.